Furthermore, the positive correlation between GYS1 and the sensitivity of a vast majority of chemotherapeutic drugs in the CTRP portal indicates that incorporating GYS1-based immunotherapy or chemotherapy into treatment strategies can enhance the likelihood of prognostic improvement for individuals with HBV-HCC. The gene discussed is GYS1; the disease is hepatocellular carcinoma.